Special Issue

Prognosis and Treatment of Cutaneous Melanoma

Message from the Guest Editors

In this Special Issue, the most relevant and updated information about characteristics that determine the prognosis of cutaneous melanomas will be addressed. This will include an in-depth analysis of factors related to the patient (genetic predisposition), as well as the pathologic and molecular characteristics of the tumor. A review of the current available evidence on adjuvant and neoadjuvant treatment and the treatment of advanced melanoma are also included in this issue.

Guest Editors

Prof. Dr. Eduardo Nagore

Department of Dermatology, Instituto Valenciano de Oncologia, 46001 Valencia, Spain

Prof. Dr. Rajiv Kumar

Division of Molecular Genetic Epidemiology, German Cancer Research Center, Heidelberg, Germany

Deadline for manuscript submissions

closed (15 June 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/88151

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

